Valion Bio Formulates Oral Mucosal Entolimod, Sees 10-40x Dose Opportunity
VBIO sits 62% above its 52-week low of $2.05.
Summary
Valion Bio and Shear Kershman Laboratories successfully formulated an oral mucosal version of Entolimod using the BioViscid platform. This creates a second delivery pathway alongside the injectable program. The company estimates the oral formulation could address 10 to 40 times the number of doses compared to injectable Entolimod, targeting military, firefighters, and law enforcement. Next study will test systemic exposure. This follows a period of activist-driven management changes and financing challenges; the milestone offers a potential expansion of the company's addressable market.
At the time of this announcement, VBIO was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.05 to $78.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.